Cancer immunotherapy: Targeting the difference

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 1175-1177

  Koh, Sarene ^a   Bertoletti, Antonio ^a,b,c  

^a AGENCY FOR SCIENCE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cancer; Immunotherapy; Tumour infiltrating lymphocytes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 INTERACTING PROTEIN; UNCLASSIFIED DRUG; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADOPTIVE TRANSFER; BILE DUCT CARCINOMA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DISEASE COURSE; GENE MUTATION; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; GENETICS; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; PROCEDURES; TRANSPLANTATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOPTIVE TRANSFER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CD4-POSITIVE T-LYMPHOCYTES; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; TH1 CELLS;

EID: 84929941274     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.023     Document Type: Note

References (10)

1. Finn OJ. Cancer immunology. N Engl J Med 2008;358: 2704-2715.
2. Coulie PG, Van den Eynde BJ, Van der Bruggen P, Boon T. Tumor antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer 2014;14: 135-146.
3. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18: 843-851.
4. Morgan RA, Chinnasamy N, Abate-daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36: 133-151.
5. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122: 863-871.
6. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Sherry RM, Schwartzentruber DJ, et al. Cell transfer therapy for cancer: Lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 2003;26: 385-393.
7. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression. J Immunol 2004;27: 184-190.
8. Kessler JH, Melief CJM. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007;21: 1859-1874.
9. Sung W-K, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44: 765-769.
10. Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2: E114.